Reckitt Benckiser Stock And Dairy Peers Under Pressure From Infant Formula Costs

Surging demand for whey protein and sharp increases in key ingredient prices are putting a new spotlight on infant formula and dairy nutrition stocks. Input costs have more than doubled for some whey components used in infant formula, squeezing margins and raising the risk of further price hikes on supermarket shelves. At the same time, reformulation trends and the possibility of regulatory caps on prices or profits add extra uncertainty for investors. This article walks through three stocks exposed to this news, all facing potential cost and policy headwinds that readers may want to factor into their positioning.

Reckitt Benckiser Group (LSE:RKT)

Overview: Reckitt Benckiser Group is a global consumer products company that sells health, hygiene and nutrition brands such as Dettol, Lysol, Durex and Enfamil, with a focus on everyday essentials that households buy repeatedly.

Operations: Reckitt Benckiser Group generates revenue of about £3.4b from Core Reckitt Europe, £2.5b from Core Reckitt North America, £4.4b from Core Reckitt Emerging Markets, £2.1b from Mead Johnson Nutrition and £1.2b from segment adjustments.

Market Cap: £33.3b

Reckitt Benckiser Group sits at the heart of the infant formula story through Enfamil, so surging whey and D90 prices directly threaten the margins that underpin its premium valuation signals, even after a sharp jump in net profit margins to 21.2% and a very high headline ROE of about 50.7% that is flattered by leverage. High debt and ongoing US legal and regulatory risks around infant formula add further pressure. Recent buybacks and dividends show management confidence, but they also increase your reliance on resilient cash flow in a tough cost and policy backdrop that the headline numbers do not fully capture yet.

Reckitt Benckiser Group’s jumpy 21.2% net margin and 50.7% ROE can mask how exposed those profits are to Enfamil costs, leverage and US legal overhangs. Before assuming the headline story holds, review the 4 key rewards and 3 important warning signs (1 is major!)

Danone (ENXTPA:BN)

Overview: Danone is a global food and beverage company based in Paris that sells yogurts, plant-based foods, bottled water and specialized nutrition products, including infant formula, medical nutrition and tube feeding, across Europe, the Americas, Asia, Africa and the Middle East.

Operations: Danone generates about €13.2b from Essential Dairy and Plant-Based Products, €9.4b from Specialized Nutrition and €4.9b from Waters.

Market Cap: €43.4b

Danone is directly exposed to the whey price squeeze because its Specialized Nutrition segment depends heavily on infant formula. At the same time, the company already carries high debt and a P/E of 22.3x that asks investors to pay a higher multiple for its earnings. Management highlights productivity initiatives and premium products, but transcripts also flag cost inflation in dairy ingredients such as whey and lactose, along with recall costs that have weighed on margins. In addition, regulators are scrutinising the infant formula category, and Danone’s bottled water and dairy exposure increases its sensitivity to input and packaging costs. For investors, the discounted fair value signals may appear appealing, but the combination of margin pressure, funding risk and tighter rules suggests that Danone merits careful analysis rather than unquestioning confidence.

Danone’s high P/E of 22.3x, rising dairy input costs and recall overhangs suggest the story might be more fragile than it looks. Before assuming the risk is already priced in, read the 4 key rewards and 1 important warning sign

Nestlé Pakistan (KASE:NESTLE)

Overview: Nestlé Pakistan is a Lahore based subsidiary of Société des Produits Nestlé that manufactures and sells a wide range of dairy, infant nutrition, beverages, bottled water, cereals and confectionery products across Pakistan and selected international markets.

Market Cap: PKR358.9b

Investors looking at Nestlé Pakistan get a mix of strong reported profitability and some uncomfortable questions. Earnings have grown 5.1% a year over five years and ROE is an exceptional 85.5%. However, the stock trades on an expensive 21.4x P/E and well above one DCF fair value estimate. Net margin of 8.2% leaves limited room for error if whey and other dairy inputs stay expensive, especially as the company is one of the world’s major infant formula producers in a sector now facing cost inflation and possible price caps. The 7.04% dividend yield may look tempting, but it is not well covered by earnings or free cash flow and the balance sheet relies fully on external borrowings, which adds another layer of risk if conditions tighten further.

Nestlé Pakistan’s high 21.4x P/E and uncovered 7.04% dividend yield could be masking deeper pressure from whey costs and leverage. Before assuming the payout holds, read the analysis report for Nestlé Pakistan

Take Control of Your Investment Journey

If Nestlé Pakistan or any of these companies are making you feel more cautious, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Everyone Else?

Fresh opportunities can move from quiet to crowded fast. Some stocks are building breakout momentum, others are dropping into rare value territory. Scan these curated shortlists before the crowd and review them now.

• Target resilient income by reviewing hand picked high yield companies inside the 5 dividend fortresses while yields and payout strength still look attractive enough to justify a closer look.
• Spot under the radar quality by assessing the 10 high quality undiscovered gems that pair solid fundamentals with share prices that have not yet caught up to their underlying businesses.
• Position for long term demand shifts by using the 29 best rare earth metal stocks focused on producers tied to critical materials that sit at the centre of major supply chains.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com